Deals of the Week: Is Botox On The Block?
Executive Summary
A pair of setbacks have sent Allergan’s stock price south, but will a buyer take advantage and buy it in a mega-deal? Also, Amgen and Servier team up in a CV deal, Forma pursues an asset-focused strategy in tandem with Cancer Research Technology, and Immunocore reveals an antibody deal with GSK.